Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Sitagliptin (Januvia) and dapagliflozin (Farxiga) are both oral medications used to treat Type 2 diabetes, but they belong to different medication classes. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Sitagliptin is taken once daily at a dose of 25 mg to 100 mg, whereas dapagliflozin is started at 5 mg daily and can be increased to 10 mg daily. Dapagliflozin is also approved to lower the risk of heart failure hospitalization and to help with chronic kidney disease, which sitagliptin is not. While sitagliptin is not known to affect body weight, dapagliflozin may cause weight loss. Common side effects of sitagliptin include a runny nose and sore throat, while dapagliflozin can cause urinary tract infections, yeast infections, and increased urination. Both medications can interact with other diabetes treatments, potentially causing low blood sugar.
Januvia (sitagliptin)
Farxiga (dapagliflozin)
Januvia (sitagliptin)
Farxiga (dapagliflozin)
Summary of Januvia vs. Farxiga
Summary for DDP-4 inhibitor
Prescription only
Januvia (sitagliptin) is a prescription medication that helps lower blood sugar in adults with Type 2 diabetes. It works best when you also follow a balanced diet and exercise regularly. It belongs to the drug class called dipeptidyl peptidase-4 (DPP-4) inhibitors, or gliptins. Januvia (sitagliptin) comes as a tablet you take by mouth once a day. Side effects include stuffy or runny nose and headache. Januvia (sitagliptin) is a brand-name medication only; the generic version isn't available yet.
Summary for SGLT2 inhibitor
Prescription only
Farxiga, the brand name for dapagliflozin, is used together with a nutritious diet and exercise plan to lower blood sugar levels in people 10 years and older with Type 2 diabetes. It can also help lower the risk of serious complications, hospitalization, and death in certain adults with heart failure or chronic kidney disease (CKD). Farxiga (dapagliflozin) belongs to the drug class called sodium-glucose cotransporter 2 (SGLT2) inhibitors. It's taken by mouth once a day. Some side effects include yeast infections, urinating more often, and weight loss.
•Type 2 diabetes (in addition to diet and exercise) in people age 10 and over
•Lowering the risk of hospitalization for heart failure in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in people with heart failure
•Lowering the risk of worsening kidney problems, hospitalization for heart failure, and death due to heart problems in adults with chronic kidney disease (CKD)